Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jody C Chuang

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Cancer|May 5, 2017
The persistent promise of combining HGF/MET and EGFR inhibition in non-small cell lung cancerJody C Chuang, Joel W Neal
Translational Lung Cancer Research|December 3, 2015
Crizotinib as first line therapy for advanced ALK-positive non-small cell lung cancersJody C Chuang, Joel W Neal
Pediatric Research|April 7, 2007
Epigenetics and microRNAsJody C Chuang, Peter A Jones
Hematology/Oncology Clinics of North America|December 4, 2016
Neoadjuvant and Adjuvant Therapy for Non-Small Cell Lung CancerJody C Chuang, Ying Liang, Heather A Wakelee
Expert Opinion on Pharmacotherapy|March 8, 2016
Rociletinib, a third generation EGFR tyrosine kinase inhibitor: current data and future directionsJody C Chuang, Ameen A Salahudeen, Heather A Wakelee
Current Treatment Options in Oncology|November 17, 2017
Anaplastic Lymphoma Kinase Testing: IHC vs. FISH vs. NGSXiaomin Niu, Jody C Chuang, Gerald J Berry, et al.
Clinical Therapeutics|July 3, 2016
Concordant and Discordant EGFR Mutations in Patients With Multifocal Adenocarcinomas: Implications for EGFR-Targeted TherapyJody C Chuang, Joseph B Shrager, Heather A Wakelee, et al.
Lung Cancer (Amsterdam, Netherlands)|August 16, 2015
Adjuvant therapy for EGFR mutant and ALK positive NSCLC: Current data and future prospectsJody C Chuang, Joel W Neal, Xiao-Min Niu, et al.
Biochemical and Biophysical Research Communications|January 1, 2009
Epigenetic therapy upregulates the tumor suppressor microRNA-126 and its host gene EGFL7 in human cancer cellsYoshimasa Saito, Jeffrey M Friedman, Yoshitomo Chihara, et al.
Cancer Cell|June 13, 2006
Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cellsYoshimasa Saito, Gangning Liang, Gerda Egger, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Cancer|May 5, 2017
The persistent promise of combining HGF/MET and EGFR inhibition in non-small cell lung cancerJody C Chuang, Joel W Neal
Translational Lung Cancer Research|December 3, 2015
Crizotinib as first line therapy for advanced ALK-positive non-small cell lung cancersJody C Chuang, Joel W Neal
Pediatric Research|April 7, 2007
Epigenetics and microRNAsJody C Chuang, Peter A Jones
Hematology/Oncology Clinics of North America|December 4, 2016
Neoadjuvant and Adjuvant Therapy for Non-Small Cell Lung CancerJody C Chuang, Ying Liang, Heather A Wakelee
Expert Opinion on Pharmacotherapy|March 8, 2016
Rociletinib, a third generation EGFR tyrosine kinase inhibitor: current data and future directionsJody C Chuang, Ameen A Salahudeen, Heather A Wakelee
Current Treatment Options in Oncology|November 17, 2017
Anaplastic Lymphoma Kinase Testing: IHC vs. FISH vs. NGSXiaomin Niu, Jody C Chuang, Gerald J Berry, et al.
Clinical Therapeutics|July 3, 2016
Concordant and Discordant EGFR Mutations in Patients With Multifocal Adenocarcinomas: Implications for EGFR-Targeted TherapyJody C Chuang, Joseph B Shrager, Heather A Wakelee, et al.
Lung Cancer (Amsterdam, Netherlands)|August 16, 2015
Adjuvant therapy for EGFR mutant and ALK positive NSCLC: Current data and future prospectsJody C Chuang, Joel W Neal, Xiao-Min Niu, et al.
Biochemical and Biophysical Research Communications|January 1, 2009
Epigenetic therapy upregulates the tumor suppressor microRNA-126 and its host gene EGFL7 in human cancer cellsYoshimasa Saito, Jeffrey M Friedman, Yoshitomo Chihara, et al.
Cancer Cell|June 13, 2006
Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cellsYoshimasa Saito, Gangning Liang, Gerda Egger, et al.
Pageof 2